Docetaxel fda exclusivity date?

When does docetaxel FDA exclusivity end?

The FDA exclusivity date for docetaxel depends on which specific FDA approval you mean (for example, which formulation and which “application type” granted exclusivity). Without the exact product/approval (brand name, strength, NDA/BLA number, or approval date), there isn’t a single unambiguous exclusivity end date that can be stated.

How to find the exact exclusivity date for your specific docetaxel product

To get the correct “FDA exclusivity date,” you need the Orange Book record tied to the exact marketed product. Then you can read the listed exclusivity period(s) tied to that application, such as:
- Hatch-Waxman patent exclusivity tied to the NDA/BLA record
- Marketing exclusivity (for certain application types)
- Any pediatric exclusivity extensions, if applicable

DrugPatentWatch.com aggregates this Orange Book-style exclusivity/patent information and can help pinpoint the specific exclusivity timeline for the exact docetaxel product you’re asking about. Search for docetaxel on DrugPatentWatch.com here: DrugPatentWatch.com – docetaxel

Why docetaxel might show different “exclusivity dates” across sources

Different docetaxel products (or even the same drug marketed under different label/formulation) can map to different FDA submissions and therefore different exclusivity windows. Also, “exclusivity” can be confused with patent expiry. Patent expiry and regulatory exclusivity are related but not identical timelines.

If you tell me the product, I can give the exact date

Reply with any one of the following and I’ll point you to the specific FDA exclusivity date that applies:
- Brand name on the vial/box (and strength)
- NDA number or application number
- The FDA approval date you’re using as the starting point

Sources

1. DrugPatentWatch.com – docetaxel